Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 14, 2013; 19(14): 2154-2161
Published online Apr 14, 2013. doi: 10.3748/wjg.v19.i14.2154
Published online Apr 14, 2013. doi: 10.3748/wjg.v19.i14.2154
Table 4 Time to first progression and time to 2nd progression according to treatment (chemotherapy or supportive) care in patients with metastatic gastric cancer (P < 0.001)
| Therapeutic approach | n | Average (mo) | Standard deviation | Minimum (mo) | Maximum (mo) |
| First series of chemotherapy and time to progression | |||||
| DCF | 152 | 6.56 | 2.869 | 1 | 18 |
| ECF | 77 | 4.56 | 9.021 | 1 | 48 |
| CF | 121 | 4.15 | 5.546 | 1 | 39 |
| Supportive | 112 | 3.85 | 9.951 | 2 | 60 |
| Others | 38 | 5.24 | 11.954 | 1 | 60 |
| Second series of chemotherapy and time to progression | |||||
| DCF | 31 | 4.38 | 3.921 | 2 | 15 |
| ECF | 14 | 3.71 | 2.443 | 2 | 10 |
| CF | 19 | 3.76 | 3.914 | 3 | 18 |
| Supportive | 267 | 3.39 | 1.871 | 1 | 12 |
| Others | 17 | 3.75 | 1.528 | 1 | 7 |
- Citation: Selcukbiricik F, Buyukunal E, Tural D, Ozguroglu M, Demirelli F, Serdengecti S. Clinicopathological features and outcomes of patients with gastric cancer: A single-center experience. World J Gastroenterol 2013; 19(14): 2154-2161
- URL: https://www.wjgnet.com/1007-9327/full/v19/i14/2154.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i14.2154